Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 487-492

  Cos, Samuel ^a   Álvarez García, Virginia ^a   González, Alicia ^a   Alonso, Carolina González ^a   Martínez, Carlos Campa ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Aromatase; Endothelial cell; Fibroblast; MCF 7; Melatonin; Pineal gland

Indexed keywords

ESTROGEN; GROWTH FACTOR; INTERLEUKIN 11; INTERLEUKIN 6; MELATONIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE CELL; BREAST CANCER; CLINICAL FEATURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; FIBROBLAST; HUMAN; PARACRINE SIGNALING; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84902316044     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2203     Document Type: Review

References (47)

1. Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170, 2000.
2. Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15: 637-647, 2000.
3. Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem 2: 113-132, 2002.
4. Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159, 2003.
5. Sánchez-Barceló EJ, Cos S, Mediavilla MD, Martínez-Campa CM, González A and Alonso-González C: Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222, 2005.
6. Cohen M, Lippman M and Chabner B: Role of pineal gland in aetiology and treatment of breast cancer. Lancet 2: 814-816, 1978.
7. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128, 2006.
8. Reiter RJ: The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1: 109-131, 1980.
9. Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 8: 1681-1690, 1994.
10. Cos S, Blask DE, Lemus-Wilson A and Hill SM: Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture. J Pineal Res 10: 36-42, 1991.
11. Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64: 249-256, 1992.
12. Cos S, Martínez-Campa C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142, 2005.
13. González A, Martínez-Campa C, Mediavilla MD, et al: Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep 17: 947-955, 2007.
14. Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278, 2006.
15. Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat 94: 249-254, 2005.
16. Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol 25: 149-156, 2000.
17. van Landeghem AA, Poortman J, Nabuurs M and Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900-2906, 1985.
18. Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654: 123-143, 2004.
19. Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93: 221-236, 2005.
20. Conley A and Hinshelwood M: Mammalian aromatases. Reproduction 121: 685-695, 2001.
21. Santen RJ and Harvey HA: Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 6: 75-92, 1999.
22. Suzuki T, Miki Y, Nakamura Y, et al: Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12: 701-720, 2005.
23. Cos S, González A, Álvarez-García V, Alonso-González C and Martínez-Campa C: Melatonin and breast cancer: selective estrogen enzyme modulator. In: Advances in Cancer Drug Targets. Atta-ur-Rahman (ed.) Vol 1. 1st Edition. Bentham Science Publishers, Sharjah (UAE), pp207-237, 2012.
24. González A, Cos S, Martínez-Campa C, Alonso-González C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92, 2008.
25. Bulun SE, Lin Z, Imir G, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57: 359-383, 2005.
26. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H and Shozu M: The human CYP19 (aromatase p450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86: 219-224, 2003.
27. Díaz-Cruz ES, Shapiro CL and Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90: 2563-2570, 2005.
28. Prosperi JR and Robertson FM: Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 81: 55-70, 2006.
29. Martínez-Campa C, González A, Mediavilla MD, Alonso-González, Álvarez-García V, Sánchez-Barceló EJ and Cos S: Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 101: 1613-1619, 2009.
30. Wang J, Xiao X, Zhang Y, et al: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 53: 77-90, 2012.
31. González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expresión in rat glioma cells. Br J Cancer 97: 755-760, 2007.
32. González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Álvarez-García V, Sánchez-Barceló EJ and Cos S: Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol Rep 23: 1173-1178, 2010.
33. González A, Álvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Tar 10: 279-286, 2010.
34. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM and Bulun SE: Tumor necrosis factor α and interleukin 11 secreted by malignant breast epitelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ: mechasnism of desmoplastic reaction. Cancer Res 61: 2250-2255, 2001.
35. Bulun SE, Chen D, Lu M, et al: Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 106: 81-96, 2007.
36. Ntambi JM and Kim YC: Adipocyte differentiation and gene expression. J Nutr 130: 3122S-3126S, 2000.
37. González A, Álvarez-García V, Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res 52: 12-20, 2012.
38. Knower KC, To SQ, Takagi K, et al: Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat 132: 765-771, 2012.
39. Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 52: 282-290, 2012.
40. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H and Takagi Y: Localized expression of aromatase in human vascular tissues. Circ Res 84: 1285-1291, 1999.
41. Mukherjee TK, Dinh H, Chaudhuri G and Nathan L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Nat Acad Sci USA 6: 4055-4060, 2002.
42. Sebastian S, Takayama K, Shozu M and Bulun SE: Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is upregulated in breast cancer tissue. Mol Endocrinol 10: 2243-2254, 2001.
43. Senger DR, Van De Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324, 1993.
44. Liang Y and Hyder SM: Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 146: 3632-3641, 2005.
45. Álvarez-García V, González A, Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates aromatase activity and expression in endotelial cells. Oncol Rep 29: 2058-2064, 2013.
46. Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Regulation of vascular endotelial growth factor by melatonin in human breast cáncer cells. J Pineal Res 54: 373-380, 2013.
47. Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic effects of melatonin in endotelial cell cultures. Microvasc Res 87: 25-33, 2013.